Evaluation and Characterization Oftumor lysis syndrome before and After Chemotherapy among pediatric Oncology patients in Tikur Anbessa Specialized Hospital
| dc.contributor.advisor | Tigeneh, Wondimagegn (PhD) | |
| dc.contributor.author | Micho, Haileleul | |
| dc.date.accessioned | 2018-06-21T08:37:41Z | |
| dc.date.accessioned | 2023-11-29T04:18:18Z | |
| dc.date.available | 2018-06-21T08:37:41Z | |
| dc.date.available | 2023-11-29T04:18:18Z | |
| dc.date.issued | 2017-08 | |
| dc.description.abstract | Background: Tumor lysis syndrome (TLS) is a life-threatening emergency disorder, caused by an abrupt release of intracellular metabolites after tumor cell death. It is characterized by a series of metabolic manifestations, especially hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. Objective: The aim of the present study was to evaluate and characterize the incidence of tumor lysis syndrome in pediatric oncology patients before and after treatment in Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia. Materials and Methods: Hospital based prospective cohort study was conducted in 61 newly diagnosed and admitted pediatric oncology patients in TASH in six moth duration. Purposive and convenient sampling technique was employed for the selection of health facility and study participants respectively. Socio-demographic data was collected by interview administered questionnaire. The patients were followed and the physical diagnosis, imaging and laboratory results were interpreted by senior physicians. Data was entered to and analyzed by SPSS version 23. Results: Out of 61 pediatric oncology patients 39(63.9%) were males. The mean (+SD) age of the pediatric patients was 6.39 (+3.67) years ranging from 2 months to 14 years. Total of 29.5% of patients were found to have TLS. There were 11.5% and 18.0% of laboratory TLS (LTLS) and clinical TLS (CTLS) cases respectively. There were 72.2% spontaneous and 27.8% treatment induced TLS. There was 23% and 21.3% cases of hyperuricemia and 4.9% and 6.6% cases of hyperkalemia incidence before and after treatment respectively. Overall two patients died, in the study period, because of TLS. Conclusion: The pediatric oncology patients in this study had a high incidence of TLS. TLS occurred irrespective of socio-demographic variability in the study participants. This suggests that every child with cancer is at a risk of developing TLS. As TLS is a life- threatening complication of malignancies, early identification of patients at risk and reducing morbidity and mortality is of crucial importance. Key words: tumor lysis syndrome, pediatric oncology, metabolic derangement, cell deat | en_US |
| dc.identifier.uri | http://etd.aau.edu.et/handle/123456789/2641 | |
| dc.language.iso | en | en_US |
| dc.publisher | Addis Ababa University | en_US |
| dc.subject | Tumor lysis syndrome; Pediatric oncology; Metabolic derangement; Cell death | en_US |
| dc.title | Evaluation and Characterization Oftumor lysis syndrome before and After Chemotherapy among pediatric Oncology patients in Tikur Anbessa Specialized Hospital | en_US |
| dc.type | Thesis | en_US |